Group items tagged

Developing a new medical drug is no small feat. It requires extensive research, knowledge, expertise in the field, rigorous testing and iteration of prototypes, and strong organizational skills to manage these tasks. It is important to use the right tools to make this process as efficient and successful as possible. With the right tools available, you can streamline development, manage resources and personnel more effectively, and maximize the chances of success. Here are some tools that might be useful when developing a new medical drug: ANALYTICAL TESTING TOOLS One of the best tools available to medical drug developers is analytical testing tools. These allow you to quickly and accurately test various components of the new medication, ensuring that it meets all safety requirements and is ready for clinical trials. As highlighted by the team behind Venogen, various methods of analyzing, chemical identification, and purity certification can be used to ensure product quality. Be sure to select a tool that can accurately analyze the specific components of your new drug. When finding analytical testing tools for your drug development process, it is important to consider the tool's scalability. Consider the size and scope of your project and select a tool that can grow with you. You can also work with experts to find the right analytical testing tools for your development needs.

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of viruses that includes Nipah virus. Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness. Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which mimics the infection in humans. Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect health from this "current and future global health threat." "The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic by accelerating the development of diagnostics, therapeutics and vaccines," he added.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan. AbbVie will stop funding the drug's development, AstraZeneca said. AbbVie's Skyrizi also treats Crohn's disease.

British health agencies have secured funding to develop a standardised approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization labelled the growing outbreak a global health emergency. The Coalition for Epidemic Preparedness Innovations (CEPI) said it would give up to $375,000 to the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Security Agency (UKHSA) to develop standard tools to assess the strength and duration of immune responses generated by current vaccines, and for tests used to detect monkeypox antibody levels. Apart from administration fees, these tools will be made freely available to the global scientific community, paving the way for a common standardised assessment between countries documenting vaccine performance against monkeypox, CEPI said. Until this year, the viral disease has rarely spread outside Africa where it is endemic. But reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe. So far, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries.

The Royal Pharmaceutical Society (RPS) has appointed Neville Carter as its new chief education and membership officer. Neville joins RPS from the Royal Society of Medicine (RSM) where he is currently director of engagement, leading a team of over 60 and responsible for creating a combined directorate accountable for education, membership, philanthropy, and business development. He has, in particular, led on the development of a digital education strategy and launched professional development training programmes for members. Prior to joining the RSM, Neville worked as director of product and sales at the British Medical Association with responsibility for membership growth, supporting corporate transformation and developing and managing member benefits and relationships with third-party providers to support revenue growth. He also has senior manager experience at the RAC and at British Airways. Commenting on the appointment, Paul Bennett, RPS CEO, said: "I'm delighted that Neville will be joining our Executive team. He brings a wealth of relevant experience and this, in combination with a strong existing education and membership team at RPS and a clear ambition to strengthen the relevant functions further, will enable the organisation to deliver a dynamic offering for our members.

Smoking increases the risk of developing schizophrenia and depression, a report by academics from the University of Bristol published on 20 June claims. It says smoking raises the risk of developing schizophrenia by between 53 per cent and 127 per cent and the risk of developing depression by from 54 per cent to 132 per cent. The authors of the report say more research is needed to identify why this is the case and that more evidence is needed to understand its impact on other mental health conditions such as anxiety or bipolar disorder. The evidence, presented at the Royal College of Psychiatrist's international congress, has been shared with the government which is currently developing a new Tobacco Control Plan for publication later this year. Action on Smoking and Health (ASH) said: "Rates of smoking are much higher among people with mental health conditions than those without, and among England's six million smokers there are an estimated 230k smokers with severe mental illness (e.g., schizophrenia and bi-polar disorder) and 1.6 million with depression and anxiety."

The Royal Pharmaceutical Society (RPS) has called on employers, governments and NHS organisations to provide pharmacists with regular protected learning time (PLT) within working hours to develop their skills in clinical delivery, education, research and leadership. RPS workforce wellbeing survey showed an average 42 per cent of pharmacists were not given any PLT, a figure which rose to 55 per cent in community pharmacy. Most were unable to engage in professional development activities as part of their working day because of their responsibility to deliver frontline clinical services to patients. This means learning is often undertaken outside of working hours, increasing pressure on individuals and impacting their work/life balance. The survey showed that 48 per cent of respondents identified a lack of PLT as negatively affecting their mental health and wellbeing and that 88 per cent were at high risk of burnout. PLT improves the quality of patient care through professional practice and reflection, helping to develop insights, maintain and refine care standards and increase confidence. It facilitates continuous professional development (CPD), ensuring that skills and knowledge are up to date.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."

The global company in information and data analytics, Elsevier launched a platform, PharmaPendium for drug candidates. It is an effective tool that provides data including complete Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval packages for drug development. The platform is supported by the FDA, the Medical Devices Agency (PMDA) and the top 20 global pharma companies. Olivier Barberan, Director of Translational Medicine Solutions spoke about how "improved access to highly relevant data plus predictive tools enhances regulatory success, safeguarding the massive investments of pharma companies." "Translation of preclinical research findings to humans in an efficient but safe way is one of the greatest challenges facing drug developers. We designed the new PharmaPendium to solve this," he added.

The Royal Pharmaceutical Society (RPS) has launched a partnership with the charity Marie Curie to develop professional standards in end of life care for community pharmacy. Available for pharmacy teams across the UK, the standards will provide a free, evidence-based framework to help community pharmacies self-assess and continuously improve their end of life and bereavement care for patients and carers. They will enable community pharmacy teams to work together to develop their own practice. RPS is setting up a professional standard steering group which will have community pharmacy experts, experts within the field of palliative and end of life care, lay members, and healthcare professionals who interact with community pharmacy. Elen Jones, director lead for palliative care work at RPS, said: "RPS has a long-term commitment, striving to ensure that people living with life-limiting conditions who are approaching the end of life have timely access to medicines and clinical support from a skilled pharmacy team. "The development of these standards, in partnership with Marie Curie, is a crucial step to support community pharmacy teams to undertake simple quality improvement measures and build upon the care they already provide to this group of patients and carers."

...there are layers of telehealth program development to unpack. Core considerations for rural telehealth program development include: state telemedicine rules and regulations, language and terminology, state parity laws, staffing and teleconsultation models, funding, broadband access, and benefits to rural communities.

Arrowhead Pharmaceuticals on Monday (November 22) entered a drug development deal with GlaxoSmithKline (GSK) under which the British drugmaker will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead said it would get an upfront payment of $120 million and is eligible for additional milestone payments including up to $190 million at first commercial sale of the product, and up to $590 million in sales-related milestone payments. The drug candidate, ARO-HSD, is currently in an early-to-mid stage trial for nonalcoholic steatohepatitis (NASH), a fatty liver disease. It is based on RNA interference technology, where genes that contribute to disease are silenced.

The British scientist who led the research underpinning AstraZeneca's coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant "very rapidly" if needed. Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent after more research in the coming weeks. "It's extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen," he told BBC radio. But if required, "The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it's needed that is something that could be moved very rapidly." In a statement, AstraZeneca said it had "developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge".

NHS England is set to roll out a new test this week that will help doctors to spot a rare form of eye cancer in babies in the womb. The NHS test developed at Birmingham Women's and Children's NHS Foundation Trust, identifies the risk of developing retinoblastoma in babies that can be monitored and treated sooner - increasing the chance of saving their eyesight and potentially their lives. The new non-invasive test can detect changes in the genes in DNA and is likely to identify around 50 infants with retinoblastoma each year, in the latest example of the NHS harnessing the power of genomics to diagnose and treat patients faster and more effectively. Non-Invasive Prenatal Diagnosis (NIPD) also means parents can be informed early in pregnancy if their child is at risk. "The blood sample test is taken from the mother before birth and tested and analysed for mutations, which can determine with almost 100 per cent accuracy if the baby will develop retinoblastoma," the NHS said.

Nuffield Trust and The King's Fund are seeking feedback from community pharmacy on their proposals for the future of community pharmacy and they are seeking feedback from community pharmacy stakeholders. The online survey is the latest opportunity for pharmacy owners, LPCs and others in the sector to engage with the project to develop a Vision for Community Pharmacy. Nuffield Trust and The King's Fund want to hear their views on their proposals, ahead of the publication of the final report later this year. The vision is critically important, as it will be used to develop the future strategy for the sector and lay the groundwork for the next Community Pharmacy Contractual Framework (CPCF) negotiations. The survey is asking for thoughts on key aspects of the vision and its recommendations. The vision has been developed by Nuffield Trust and The King's Fund following an extensive programme of research, interviews and meetings of the vision Steering Group, Advisory Panel, and Working Groups, all of which have contractors, LPCs and other representatives of the sector at their heart. The vision project team are looking forward to hearing views from across the sector on their proposals and what will need to happen to make them a reality.

Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.